Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UroGen PharmaLTS:0XOD +1.27%55 Cash Ratio is 1.74 as of Jun. 2026, which is 72% below its 10-year median of 6.29. GuruFocus rates LTS:0XOD with a GF Score™ of 55/100 and a GF Value™ of $29.06 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,381 Biotechnology companies, UroGen Pharma ranks worse than 61.91% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
UroGen Pharma Cash Ratio Related Terms
UroGen Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0XOD vs PVLA, KLRA, VCEL: Cash Ratio Comparison
For the Biotechnology subindustry, UroGen Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (LTS:0XOD) has a Cash Ratio of 1.74 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on UroGen Pharma and its competitors. This is 72% below median its historical median of 6.29. Over the past decade, UroGen Pharma's Cash Ratio has ranged from 1.74 to 24.00. According to the industry distribution chart, UroGen Pharma ranks #855 out of 1381 companies in the Biotechnology industry, placing it in the top 61.9%.
Is UroGen Pharma's Cash Ratio too high?
UroGen Pharma's current Cash Ratio of 1.74 is 72% below median its 10-year median of 6.29. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 24.00. The Biotechnology industry median Cash Ratio is 2.96. UroGen Pharma's value of 1.74 is 41.2% below this industry median. Based on the distribution chart, UroGen Pharma ranks #855 out of 1381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Cash Ratio compare to PVLA and KLRA?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #855 out of 1381 companies for Cash Ratio. This places UroGen Pharma in the lower half of its industry. The industry median Cash Ratio is 2.96. UroGen Pharma's value of 1.74 is 41.2% below this benchmark. Historically, UroGen Pharma's own Cash Ratio has ranged from 1.74 to 24.00 over the past decade. While the company's 10-year median is 6.29 vs. the industry median of 2.96, UroGen Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Cash Ratio of 1.74 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Cash Ratio is 1.74, which is 72% below median its own 10-year median of 6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.06, compared to a current price of $42.77 — trading 47.2% above its estimated fair value. The current Cash Ratio is 1.74, which is 72% below median its 10-year median of 6.29 and 41.2% below the Biotechnology industry median of 2.96. UroGen Pharma's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Cash Ratio is 1.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $42.77 is trading 47.2% above its estimated GF Value™ of $29.06.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
Cash Ratio: 1.74 (72% below median its 10-year median of 6.29)
GF Value™: $29.06 vs. price of $42.77 (47.2% above fair value)
Industry Position: 41.2% below the Biotechnology median (#855 of 1381)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
55GF Score
Get the complete analysis for LTS:0XOD
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
